Overexpression of Smad7 in intestinal macrophages is associated with their pro-inflammatory activation [11], and shRNA-mediated knockdown of Smad7 is currently being tested as a therapy for inflammatory bowel disease [12]. This evidence concerns the gene SMAD7 and inflammatory bowel disease.